Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$20.8 million.

  • Regenxbio's Net Cash Flow fell 170801.39% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 3471.77%. This contributed to the annual value of $23.0 million for FY2024, which is 13684.77% up from last year.
  • Per Regenxbio's latest filing, its Net Cash Flow stood at -$20.8 million for Q3 2025, which was down 170801.39% from -$50.5 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Net Cash Flow registered a high of $117.5 million during Q4 2021, and its lowest value of -$153.3 million during Q1 2022.
  • In the last 5 years, Regenxbio's Net Cash Flow had a median value of -$20.8 million in 2025 and averaged -$14.7 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 4547669.9% in 2021, then surged by 39207.03% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Net Cash Flow stood at $117.5 million in 2021, then crashed by 118.37% to -$21.6 million in 2022, then rose by 13.17% to -$18.7 million in 2023, then skyrocketed by 104.85% to $909000.0 in 2024, then crashed by 2383.39% to -$20.8 million in 2025.
  • Its Net Cash Flow was -$20.8 million in Q3 2025, compared to -$50.5 million in Q2 2025 and $72.6 million in Q1 2025.